- Home
- CIO vs CKPT Comparison
CIO vs CKPT Comparison
Compare CIO & CKPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CIO
- CKPT
- Stock Information
- Founded
- CIO 2013
- CKPT 2014
- Country
- CIO Canada
- CKPT United States
- Employees
- CIO N/A
- CKPT N/A
- Industry
- CIO Real Estate Investment Trusts
- CKPT Biotechnology: Pharmaceutical Preparations
- Sector
- CIO Real Estate
- CKPT Health Care
- Exchange
- CIO Nasdaq
- CKPT Nasdaq
- Market Cap
- CIO 202.0M
- CKPT 172.4M
- IPO Year
- CIO 2014
- CKPT 2017
- Fundamental
- Price
- CIO $5.16
- CKPT $4.04
- Analyst Decision
- CIO
- CKPT Buy
- Analyst Count
- CIO 0
- CKPT 3
- Target Price
- CIO N/A
- CKPT $4.33
- AVG Volume (30 Days)
- CIO 179.8K
- CKPT 5.7M
- Earning Date
- CIO 05-02-2025
- CKPT 03-28-2025
- Dividend Yield
- CIO 7.69%
- CKPT N/A
- EPS Growth
- CIO N/A
- CKPT N/A
- EPS
- CIO N/A
- CKPT N/A
- Revenue
- CIO $171,126,000.00
- CKPT $41,000.00
- Revenue This Year
- CIO $0.98
- CKPT $102,182.93
- Revenue Next Year
- CIO $3.56
- CKPT $351.71
- P/E Ratio
- CIO N/A
- CKPT N/A
- Revenue Growth
- CIO N/A
- CKPT N/A
- 52 Week Low
- CIO $4.29
- CKPT $1.38
- 52 Week High
- CIO $6.50
- CKPT $4.50
- Technical
- Relative Strength Index (RSI)
- CIO 52.41
- CKPT 65.90
- Support Level
- CIO $5.10
- CKPT $2.37
- Resistance Level
- CIO $5.33
- CKPT $4.07
- Average True Range (ATR)
- CIO 0.17
- CKPT 0.03
- MACD
- CIO 0.02
- CKPT 0.01
- Stochastic Oscillator
- CIO 72.39
- CKPT 70.00
About CIO City Office REIT Inc.
City Office REIT Inc is a real estate investment trust. It is focused on acquiring, owning, and operating high-quality office properties located predominantly in Sun Belt markets. The principal objective of the company is to provide attractive risk-adjusted returns to its investors over the long-term through a combination of dividends and capital appreciation. The company owns office buildings in the metropolitan areas of Dallas, Denver, Orlando, Phoenix, Portland, Raleigh, San Diego, Seattle, and Tampa.
About CKPT Checkpoint Therapeutics Inc.
Checkpoint Therapeutics Inc is an immuno-oncology biopharmaceutical company based in the USA. It focuses on the acquisition, development, and commercialization of novel, non-chemotherapy, immune-enhanced combination treatments for patients with solid tumor cancers. Its licensed portfolio of antibodies includes targeting programmed cell death-ligand 1 (PD-L1), glucocorticoid-induced TNFR-related protein (GITR) and carbonic anhydrase IX (CAIX). The company is evaluating its lead small-molecule, targeted anti-cancer agent, olafertinib, a third-generation epidermal growth factor receptor ("EGFR") inhibitor, as a potential new treatment for patients with EGFR mutation-positive non-small cell lung cancer.